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ABSTRACT 
 
Twin-screw extruder has attracted considerable attention in the pharmaceutical industry 
as an alternative processing instrument due to its advantages compared to other conventional 
equipment, such as economical processing, small footprint, reduced in-process times, solvent-
free and continuous processing. These superiorities have led to the application of twin-screw 
extruder to produce numerous dosage forms, including pellets, tablets and films. Many other 
formulations production can also be beneficial from the introduction of twin-screw extruder to 
the process.  
Nanocrystal formulations are promising drug delivery systems owing to their ability to 
enhance the bioavailability and maintain the stability of poorly water-soluble drugs. However, 
conventional methods of preparing nanocrystal formulations, such as spray drying and freeze-
drying, have some drawbacks, including high cost, time and energy inefficiency, traces of 
residual solvent. In this study, twin-screw extruder was combined with high pressure 
homogenizer to successfully produce nanocrystal solid dispersions (NCSDs). The process could 
successfully overcome the limitation of conventional methods. 
Dry granulation process is necessary for some moisture sensitive APIs. However, the 
widely applied dry granulation technologies, slugging and roller compaction, have some 
limitations: single batch operation, low manufacturing throughput, high amounts of fines and 
dust, inferior tensile strength of final tablet and loud operation. The previously unreported study 
of applying twin screw extruder to the dry granulation process was successfully conducted. The 
iii 
continuous processing nature, simplicity of operation and easiness of optimization made (twin-
screw dry granulation) TSDG quite competitive compared to other conventional dry granulation 
techniques. 
Kollidon® SR is a polyvinyl acetate (PVAc) and polyvinyl pyrrolidone (PVP) based 
polymer. The plastic PVAc and sticky PVP make Kollidon® SR an extraordinary option for 
direct compression of high hardness and low friability tablet. In addition, the low glass transition 
temperature (Tg) of about 35 oC should make Kollidon® SR a perfect candidate for twin screw 
extruder. But this application is rarely reported. This study demonstrated Kollidon® SR could be 
successfully processed by twin-screw extruder to produce tablets, which is compared to the 
direct compressed counterpart. The physicochemical properties of both products were analyzed. 
The drug release mechanism was determined. 
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CHAPTER 1. 
INTRODUCTION 
2 
1.1. Hot Melt Extrusion 
In the plastics industry, Hot melt extrusion (HME) has been utilized since the late 1930s, 
and still dominates the production of numerous plastic products. The technique was introduced in 
pharmaceutical industry after approximately four decades [1-6]. Since then, HME has attracted 
considerable attention in the pharmaceutical industry due to its inherent advantages, such as 
being a solvent-free, continuous process with no time consuming steps, ease to scale up, 
compared to other conventional techniques [7, 8]. Generally speaking, HME is a process that raw 
materials (mixture of APIs, excipients and other additives) are propelled with spinning screw(s) 
under high shear and temperature, and products are collected through a die block with a specific 
shape (Figure 1-1) [7, 9-12]. However, the application of HME is not limited to extrudates. 
Instead, HME has been modified, or combined with downstream processing equipment, to make 
a variety of dosage forms, including pellets [13], tablets [14], transdermal films [15, 16], 
implants [17], granules[18-21] and solid lipid nanoparticles (SLN) [22, 23]. 
HME, as a fusion based method to produce solid dispersions, could not avoid the intrinsic 
limitation of this type of techniques. Fusion based technique is simply a process to heat the raw 
materials to a specific high temperature and then cool the materials at a controlled rate [24-30]. 
Thus, the thermal stability of the material to be processed is be a prerequisite [1, 31-36]. 
Otherwise, the high temperature applied may cause the unacceptable thermal degradation of the 
materials used [37]. As a result, HME could barely utilized for processing of heat sensitive 
substances, such as proteins and peptides. 
3 
 
Figure 1-1. HME equipment and process parameters traditionally monitored during 
pharmaceutical HME. (1. Feeding system; 2. Feeding hopper; 3. Temperature controlled barrel 
with 1 or 2 screws; 4. Die; 5. Heating and cooling device; 6. Screw-driving unit).[10] 
 
1.1.1. Twin Screw Extruder 
Based on number of screws, hot melt extruder can be classified into two categories: 
single screw extruder (SSE) and twin screw extruder (TSE) (Figure 1-2) [8, 13, 38-41]. As the 
names straightforwardly indicate, SSE utilize one rotating screw and TSE has two screws side by 
side in the barrel. SSE is the most widely used extrusion extruder, especially in plastics industry, 
due to the advantage of mechanical simplicity and more affordable cost. However, TSE is still 
the more popular system in the pharmaceutical industry, owing to a series of benefits, including 
4 
high kneading/dispersing capacities, shorter transit time, less tendency to over-heat and easier 
material feeding. [6] 
TSE can further be divided into two categories based on the direction of screw rotation 
(co-rotating or counter-rotating). Counter-rotating design works best for situation that very high 
shear force or dispersion of particles in a blend is needed. Co-rotating design is suitable for the 
needs of high screw speeds, high production and self-wiping. 
 
 
Figure 1-2. Cross-section of single- and twin-screw extruders. [8] 
 
1.2. Solubility Threshold 
More than 40 % of drugs developed by the pharmaceutical industry are poorly soluble in 
water [42, 43]. With the introduction of high-throughput screening (HTS) methods for the 
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discovery of new drugs [44], the amount of poorly water-soluble drugs is increasing rapidly. 
Most drugs are administrated orally, as it is the most common and convenient route for drug 
delivery, so poor solubility often leads to poor gastrointestinal absorption, and thus poor 
bioavailability [35, 45]. Solubility is also a critical parameter to be considered in parenteral 
formulations [46]. Thus, enhancement of the dissolution rate of poorly soluble drugs remains one 
of the most challenging tasks for pharmaceutical scientists.  
 
1.2.1. Dissolution Rate Improvement 
Various approaches have been employed to improve the dissolution rate of certain poorly 
water-soluble drugs. For example, salt formation is a chemical method used to make a drug into 
a prodrug to improve the dissolution rate [47]. However, this method can only be applied to 
weakly acidic or basic drugs, not those with neutral pH [35]. Incorporating drug molecules into 
cyclodextrin is also an effective way to enhance their dissolution rate, but this method requires a 
certain molecular size and conformation [48, 49]. The currently available dissolution rate 
enhancement methods are limited to drugs with certain properties, such as acid-base property, 
molecular size and conformation. 
 
1.2.2. Solid Dispersion 
Production of a solid dispersion (SD) is one of the most extensively studied methods of 
improving the dissolution rate of poorly soluble drugs [50-56]. A SD can be defined as a solid 
system of a poorly water soluble drug or drugs dispersed in an inert carrier, with the drug usually 
in the amorphous state [35, 57]. The amorphous form of drug usually has more free energy than 
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the crystalline counterpart, which leads to an increased dissolution rate [58]. However, this high 
free energy also tends to create thermodynamic instability, which is a major drawback of 
amorphous SDs. Recrystallization is usually observed during the storage of SDs [58-60]. 
 
1.2.3. Nanocrystal Solid Dispersion 
In order to solve the recrystallization problem, initially formulating drugs into a 
crystalline state in a smaller size is a feasible method. It has been reported that the micronization 
of drug powders to particle sizes of between 1 and 10 μm is not sufficient to overcome 
bioavailability problems of very poorly soluble drugs [61], so the natural progression is to move 
from micronization to nanonization, the production of nanocrystals [62-75]. Nanocrystals are 
crystals with a particle size below 1000 nm. The reduction in particle size increases the surface 
area, which directly affects the dissolution rate. Thus, by decreasing the particle size, a higher 
dissolution rate can be achieved. This can be explained with the help of the Noyes–Whitney 
equation:  
𝑑𝑊
𝑑𝑡
=
𝐷𝐴(𝐶𝑠−𝐶)
𝐿
 [76] 
where dW/dt is the rate of dissolution, A is the surface area of the solid, C is the 
concentration of the solid in the bulk dissolution medium, Cs is the concentration of the solid in 
the diffusion layer surrounding the solid, D is the diffusion coefficient, and L is the diffusion 
layer thickness. 
However, it has been reported that decreasing the particle size below a critical value of 1–
2 μm increases the saturation solubility [61]. This can be derived from the Kelvin equation, 
below, which is usually used to describe the vapor pressure of a curved droplet but can also be 
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used to describe the dissolution process, in which Ƥ and Ƥo represent the actual and saturated 
dissolution pressure:  
ln
𝑝
𝑝0
=
2γ𝑉𝑚
𝑟𝑅𝑇
 [77] 
where Ƴ is the surface tension, Vm is the molar volume of the liquid, R is the universal 
gas constant, r is the radius of the particle, and T is the temperature. As can been seen from the 
equation, Ƥ directly depends on r. A decrease in r means a decrease in the particle size, which 
will increase the saturated dissolution pressure and thus increase the saturated solubility. 
 
1.2.4. Production of Nanocrystal Solid Dispersion 
The methods for production of nanocrystals can be divided into two basic types: bottom-
up technologies (controlled precipitation/crystallization) and top-down technologies (media 
milling/high pressure homogenization [HPH]) (Figure 1-3) [70, 72]. Currently, five nanocrystal 
products have been approved by the US FDA, all of which are based on top-down technologies 
(four of these products are prepared by wet-ball milling and one is prepared by high-pressure 
homogenization) [73], which indicates that the top-down process is more industrially feasible 
[65]. After completion of these processes, the drugs are present in a suspended state as a 
nanosuspension (NS). However, it is usually important for the NS to be transformed into a solid 
product, both for physical stability and patient convenience [66, 73]. The most widely used 
processes for transformation include freeze-drying and spray-drying [78]. However, these two 
methods have several disadvantages, such as high cost, time and energy inefficiency, and 
residual solvent trace [1]. There is therefore a need for a new technology to complete the 
transformation process. HME is considered as a promising technique for this objective based on 
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the advantage mentioned in section 1.1. In addition, the preparation of nanocrystal solid 
dispersions (NCSDs) by combing HPH and HME is not yet explored much [79].  
 
 
Figure 1-3. Bottom up or top down approach to preparing nanocrystals.[70] 
 
1.3. Granulation 
Based on Perry’s Chemical Engineer’s Handbook, granulation process was defined as 
“any process whereby small particles are gathered into larger, permanent masses in which the 
original particles can still be identified” [80]. Granulation is widely utilized in numerous 
industries, such as agriculture, mining, chemical, pharmaceutical and food industry [81]. The 
application of granulation process in pharmaceutical industry was triggered by the invention of 
tablet press in 1843 [82]. Nowadays, granule has become a very important intermediary before 
tablet compression and capsule filling [83-85]. The main purpose of granulation in 
pharmaceutical industry is to convert small API and excipient particles into larger agglomerates, 
9 
which have some beneficial physicochemical properties, such as better flow properties, more 
uniform drug distribution, reduced dust, prevention of segregation, increased compactability and 
enhanced appearance of product [86-89]. 
 
1.3.1. Wet Granulation 
Wet granulation, which is employed to produce 70% of the worldwide industry’s 
granules [86], is the most popular granulation technique in pharmaceutical industry, owing to 
lots of available knowledge and equipment. In general, wet granulation comprises of several 
steps: liquid binder addition, agglomeration, drying and screening [90-93]. The aggregation of 
primary particulates is achieved by the liquid binder [90]. Melt granulation is considered as a 
particular form of wet granulation as the mechanism of these two methods are similar [83, 94]. 
However, the limitation of wet granulation is also obvious, such as multiple unit feature, time 
inefficiency, high cost, large space requirement and especially unsuitability for moisture 
sensitive APIs [90-92]. Thus an alternative technology of dry granulation is necessary [95]. 
 
1.3.2. Dry Granulation 
Unlike wet granulation, dry granulation employs dry binders and high mechanical force 
to enable the agglomeration process [83, 90, 96]. Slugging and roller compaction are two widely 
used dry granulation techniques in the pharmaceutical industry (Figure 1-4) [86, 90, 95-98]. 
Slugging wa the favorable dry granulation technique in the 1950s-1970s in the pharmaceutical 
industry [96]. In this process, the primary powders are compressed into large tablets or slugs, 
followed by the milling and sieving process. The quality of granules highly depends on the flow 
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ability of raw materials, which may cause the inhomogeneity problem [86]. Other disadvantages 
of slugging include: single batch processing, low manufacturing throughput, frequent 
maintenance and so on. Compared to slugging, an auger-feed system is utilized in roller 
compaction to constantly deliver raw material, which can ensure the good content uniformity of 
granules. In addition, roller compaction is a highly efficient and continuous process, which has a 
much higher output than slugging. Thus, roller compaction is considered as a more competitive 
dry granulation technique in pharmaceutical plants. Although roller compaction shows many 
advantage over slugging, it is not perfect. It has been reported that this method also comprises 
some disadvantages, including relative high amount of fines and dust [86, 99-101], inferior 
tensile strength of final tablet [88, 89, 98, 100] and loud operation environment [86]. Therefore, 
there is an increasing need for an alternative dry granulation technique that can solve the 
problem mentioned above.  
 
1.3.3. Twin Screw Granulation 
The benefits of TSE have led to innumerable application in the pharmaceutical industry, 
including wet granulation [18, 21] and melt granulation [20, 102]. The only difference between 
twin screw granulation (TSG) and TSE is that the die is removed during the process to prevent 
the extreme densification of material inside the barrel. The successful application of twin screw 
extruder on wet and melt granulation can be a positive indication that dry granulation could also 
be efficaciously accomplished utilizing this technique. 
11 
 
Figure 1-4. Schematic diagram of dry granulation and two different techniques. [90] 
 
1.4. Kollidon® SR 
Kollidon® SR (Figure 1-5) is one type of polyvinyl acetate (PVAc) and polyvinyl 
pyrrolidone (PVP) based polymer, which is especially appropriate for the production of pH-
independent sustained release formulations [62]. The two major compositions of Kollidon® SR 
are 80 % of PVAc and 19 % of PVP (Kollidon® 30). Other than that, about 0.8 % of sodium 
laury sulfate (SLS) and 0.2 % of silica serve as stabilizers for the whole physical mixture [103]. 
The plastic nature of PVAc guarantees the production of coherent tablet even under low 
compression forces. In addition, the sticky PVP can tightly bind materials together. Combining 
12 
these properties together, Kollidon® SR shows the outstanding property of compression and 
production of high hardness and low friability tablet. Moreover, the excellent flowability of 
Kollidon® SR itself, as well as the potential to improve the flowability of other material added to 
the formulation, make Kollidon® SR a competitive candidate for direct compression, Therefore, 
numerous sustained release tablets have been produced using Kollidon® SR by direct 
compression method [104-107]. 
 
 
Figure 1-5. Chemical structure of Kollidon SR. 
 
1.4.1. Processing Kollidon® SR by Twin Screw Extruder 
The application of Kollidon® SR on HME was rarely reported. This phenomenon is quite 
eccentric, because the low glass transition temperature (Tg) of about 35 oC should make this 
polymer a perfect contender for HME. To the author’s knowledge, only two manuscripts, whose 
topic was on utilization of Kollidon® SR for HME, were published [108, 109]. 
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CHAPTER 2. 
CONJUGATION OF TWIN SCREW EXTRUTION WITH HIGH PRESSURE 
HOMOGENIZATION: A NOVEL METHOD OF PREPARING NANOCRYSTAL SOLID 
DISPERSIONS 
14 
2.1. Objective 
The primary objective of this study was to develop a new method of preparing a NCSD 
by applying TSE after HPH. The first step was to prepare a NS using HPH. The resulting 
suspension was extruded utilizing TSE with the help of a selected polymer (Soluplus®) to obtain 
a NCSD. In addition, various physical and chemical properties were evaluated within the NCSD. 
Finally, the stability of the NCSD was studied. 
 
2.2. Materials 
Efavirenz (EFZ) was purchased from Ria International LLC (East Hanover, NJ, US). SLS 
was purchased from Fisher Scientific (Hanover Park, IL, US). Kollidon® 30 and Soluplus® were 
kindly donated by BASF SE (Ludwigshafen, Germany). All other reagents used in this study 
were of analytical grade. 
 
2.3. Methods 
2.3.1. Preliminary Study 
A preliminary study was carried out to evaluate the formulation and process parameters 
to be used in the preparation of the NCSD. The three most critical parameters in the HPH process 
were found to be drug concentration, homogenization pressure, and time, while in the TSE 
process, the parameters taken into consideration were the ratio of NS to polymer, feeding rate, 
barrel temperature, screw configuration, screw speed, and zone for NS addition. All of these 
parameters were optimized to successfully prepare a NCSD by HPH-TSE technique. 
15 
2.3.2. Preparation of EFZ NS 
EFZ NS was prepared by HPH technique. Briefly, different concentrations of EFZ 
powder (2 % and 4 %, w/v) were poured into an aqueous surfactant solution (Kollidon® 30, 1.0 
% w/v and SLS 0.5 % w/v) [110], and further mixed on a magnetic stirrer at 500 rpm for 12 h in 
order to achieve complete dispersion of EFZ in the solution. After dispersion, the mixtures were 
homogenized using a T25 digital ULTRA-TURRAX® basic homogenizer (IKA-Werke, Staufen, 
Germany) at 15000 rpm for 5 min. The resulting suspension was further homogenized using an 
EmulsiFlex-05 high-pressure homogenizer (Avestin Inc., Ottawa, Canada) at 1500 bar for 
selected cycles. 
 
2.3.3. Preparation of EFZ NCSD 
NCSD was prepared by mixing aqueous phases of NS and polymer (Soluplus®) using an 
11-mm co-rotating twin-screw extruder (Thermo Fisher Scientific, Waltham, MA, US). The 
extruder consists of eight zones, the individual temperature of which, excluding zone 1, can be 
precisely controlled. The barrel was maintained within a temperature range of 100–140 °C. 
Soluplus® was fed into the extruder via an 11-mm single screw feeder (Thermo Electron, 
Karlsruhe, Germany) at a feeding rate of 1 % (approximately 1.2 g/min). NS was injected into 
zone 5 using a 520S pump (Watson Marlow, Golden, Colorado, US) at 0.3 rpm (approximately 
0.6 g/min). The screw speed was set at 50 rpm. 
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2.3.4. Characterization and Evaluation 
2.3.4.1. Solubility of EFZ 
The solubility of EFZ was assessed at room temperature. EFZ (20 mg) was added to glass 
vessels containing 20 mL of ultra-purified water. The glass vessels were then placed on an MTS 
2/4 microtiter shaker (IKA, Wilmington, NC, US), which was operated at a speed of 200 min-1 
for 24 h. The samples were then withdrawn and centrifuged at 6000 rpm for 5 min. The 
supernatant was analyzed using a GENESYS 6 UV-Vis spectrophotometer (Thermo Scientific, 
Madison, WI, US). The experiment was then repeated at least three times for all the samples. The 
means and standard deviations were then calculated. 
 
2.3.4.2. Particle Size and Zeta Potential 
As stated above, particle size can significantly affect the dissolution velocity and 
saturation solubility. Zeta potential is one of the critical parameters affecting the stability of NS 
[111]. These two parameters were measured using a Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK). The NS sample was first diluted with sufficient ultra-purified water, then 
the diluted sample was transferred to a cuvette for measurement. Dynamic light scattering was 
used to measure the Z-average (particle size) and polydispersity index (PDI). Laser doppler 
micro-electrophoresis was used to measure the zeta potential. The parameters used for 
measurement were scattering angle of 173°, refractive index of 1.33, viscosity of 0.89 cP, and 
temperature of 25 °C. 
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2.3.4.3. Loss on Drying 
Soluplus® was extruded using identical processing conditions to those used for NCSD, 
then NCSD and Soluplus® were subjected to a loss on drying (LOD) test using a MB45 Moisture 
Analyzer (Ohaus, Switzerland) by heating at 110 °C for 10 min. 
 
2.3.4.4. Differential Scanning Calorimetry 
A Diamond DSC (PerkinElmer, Shelton, CT, US) was used to measure the degree of 
crystallinity of the samples. The instrument’s Pyris manager software was utilized to analyze the 
data. About 2–5 mg of sample was weighed and hermetically sealed in an aluminum pan. The 
heating rate was set at 20 °C/min from 20 to 200 °C under an inert atmosphere of nitrogen at a 
flow rate of 20 mL/min. 
 
2.3.4.5. Drug Content 
The extrudate was first milled to a fine powder. Accurately weighed powder (10 mg) was 
dissolved in 10 mL of methanol, and then diluted 10 times with methanol. The sample was 
analyzed by UV-Vis spectrophotometry. 
 
2.3.4.6. Scanning Electron Microscopy 
Scanning electron microscopy (SEM) was used to determine the morphology of pure EFZ 
and EFZ NCSD. Adhesive carbon tape was used to mount the sample onto an aluminum stage, 
then the samples were sputter coated with gold under an argon atmosphere using a Hummer 6.2 
Sputter Coater (Ladd Research Industries, Williston, VT, US). The coater was kept in a high-
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vacuum evaporator equipped with an omni-rotary stage tray to guarantee a uniform coating. 
Finally, images were captured using a JSM-5600 scanning electron microscope (JEOL USA, 
Inc., Waterford, VA, US) at an accelerating voltage of 5 kV. 
 
2.3.4.7. In Vitro Drug Release Study 
The dissolution media used was 900 mL of 0.2 % SLS in 0.1 M HCl (pH 1.2, simulated 
gastric medium) [112]. SR8-plus™ dissolution apparatus (Hanson, Chatsworth, CA, US) was 
maintained at 37 ± 0.5 °C and the paddle speed was set at 50 rpm. Milled extrudates equivalent 
to 10 mg of EFZ were filled into capsules (size 0) for dissolution. Samples were collected at 
intervals of 5, 15, 30, 60, and 120 min through a stainless steel cannula with a 0.2-µm nylon 
filter tip attached to a 2.5-mL syringe. The samples were analyzed directly using a UV-Vis 
spectrophotometer. 
 
2.3.4.8. UV Analysis 
Samples were analyzed using a GENESYS 6 UV-Vis Spectrophotometer (Thermo 
Scientific, Madison, WI, US) at a wavelength of 247 nm. The standard curve was linear over the 
range of 1–50 μg/mL with an R2 equal to 0.9998. 
 
2.3.4.9. Stability Test 
Stability studies were conducted to determine the effect of storage on the physical and 
chemical properties of the drug in two formulations (see Table 2-1 for formulation 
compositions). Milled extrudates were stored in screw-capped glass vials at real-time storage 
19 
conditions (25 °C/60 % relative humidity [RH]). Samples were taken at 1, 2, 3, and 6 month 
intervals and characterized by dissolution and micromeritics studies. For the micromeritics 
studies, the extrudates were dispersed in ultra-purified water and then vortexed for 30 sec. The 
resulting dispersions were then analyzed using a Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK). 
 
Table 2-1. Formulation compositions of NS and extrudate. 
Formulation 
Soluplus® Kollidon® 30 SLS EFZ 
% (w/w) 
% (w/v) for NS, 
% (w/w) for 
extrudate 
% (w/v) for NS, 
% (w/w) for 
extrudate 
% (w/v) for NS, 
% (w/w) for 
extrudate 
NS 
A N/A 1.0 0.5 2.0 
B N/A 1.0 0.5 4.0 
Extrudate 
A 98.25 0.5 0.25 1.0 
B 97.25 0.5 0.25 2.0 
EFZ: efavirenz; NS: nanosuspension; SLS: sodium lauryl sulfate. 
 
2.4. Results and Discussion 
2.4.1. Preparation of EFZ NS 
Three different drug loadings (2%, 4%, and 8% w/v) were assessed to determine the 
highest drug content that can be used for NS. Before the HPH process, a regular homogenizing 
process (using a ULTRA-TURRAX® basic homogenizer) was carried out to pre-treat the EFZ 
dispersion. This method significantly reduced the processing time for HPH as the size reduction 
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was partially completed. The 2% formulation did not block HPH during processing. However, 
HPH blockage was observed during the first few cycles of 4% formulation processing. This issue 
was easily fixed by pre-treating the formulation using a regular homogenizer. However, this was 
not true in the case of the 8% formulation as it blocked the HPH during processing, even after 
pretreatment, indicating that 8% drug loading was too high for the HPH used in this study. Thus, 
the highest drug loading that was used was 4%. 
Different cycles of homogenization were carried out to determine the optimum 
homogenization parameters (Figure 2-1). The particle size of NS A (2% drug loading) was stable 
at around 320 nm after 20 homogenization cycles. Even after a few more homogenization cycles, 
there was no significant decrease in the particle size. Apart from particle size, polydispersity 
index (PDI) is also a very important parameter for NSs. A small PDI value indicates a narrow 
size distribution, whereas a high PDI value indicates a broad size distribution. Usually, a PDI 
value below 0.5 is acceptable [113]. The HPH process was optimized and after 25 
homogenization cycles for NS A the PDI value decreased to below 0.5. Similarly, the HPH 
process was optimized for NS B (4% drug loading), and after 45 homogenization cycles the 
particle size was stable at around 350 nm and the PDI value was below 0.5. It has been 
previously reported that a zeta potential of ±20 mV is sufficient to make a dispersion physically 
stable [114]. In this study, the zeta potentials for all resulting homogeneous materials were in the 
range of -20 to -30 mV, indicating that Kollidon® 30 and SLS were able to maintain the zeta 
potential within the desired range. 
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Figure 2-1. Particle size vs. cycle curves for nanosuspension A and B. 
 
2.4.2. Selection of Suitable Polymers 
The first step of the TSE process was to choose an appropriate polymer. It is critical that 
the selected polymer is stable at the extrusion temperature and has the appropriate thermoplastic 
behavior to make extrusion possible (extrudable) [115]. The glass transition temperature (Tg) is 
an important parameter affecting the extrudability of polymers because a high Tg will require a 
high temperature for processing, and in such situations the API may degrade [116]. As per the 
literature, the suitable Tg range for the TSE process is considered to be between 50 – 180 °C 
[117]. 
However, in this study, the Tg requirement is even more stringent. EFZ is a poorly water-
soluble (9.2 μg/mL, pH 8.7, 25 °C) lipophilic (log P = 5.4) drug with a crystalline state. The 
melting temperature (Tm) of EFZ is around 140 °C [118]. To maintain the crystalline state of 
EFZ, the TSE operating temperature must be kept below 140 °C. Generally, the extrusion 
22 
process is carried out at least 20–40 °C above the Tg [119], thus there is a need to choose a 
polymer with a Tg below 100 °C. It is also important that the polymer is soluble in water in order 
to produce a homogeneous NCSD. Finally, there is a period when only the polymer is present in 
the barrel, so the operation temperature for the pure polymer is another important parameter.  
Only a few polymers satisfy the above-mentioned requirements, including Soluplus®, a 
graft copolymer composed of polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol. It is 
polymeric solubilizer with an amphiphilic chemical structure, making it an excellent solubilizer 
for poorly water-soluble drugs in aqueous media. Furthermore it has a low Tg of about 70°C, 
which also makes it a suitable choice for this study [120]. The approximate temperature range for 
pure Soluplus® for use in TSE was reported to be in the range of 120–200 °C [121]. 
 
2.4.3. Experimental Set Up 
A schematic illustration of NCSD production by HPH-TSE technique is shown in Figure 
2-2. Two parts were included in this system, a high-pressure homogenizer and a twin-screw 
extruder. For this study, we used a modified screw configuration, as shown in Figure 2-3.  
The first zone of the extruder was used for feeding the polymer (Soluplus®) into the 
extruder barrel using a feeding hopper. The elements used in this section were 2.0 L/D feed 
screws (conveying elements), which had sufficient free volume to take in the purging material 
for cleaning after processing. The 1.0 L/D feed screws in zone 2 were used to compact the 
polymer and transport it forward. The temperature of 140 °C applied to this section assisted in 
the melting of the polymer, thus decreasing the torque in the next mixing zone. The temperature 
of zone 3 was set at the same value as that of zone 2. Three kinds of mixing elements with 30°, 
60°, and 90° offset angles were successfully assembled and installed in the barrel. This setting 
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provided enough energy for the melting of the polymer and avoided any rapid increase in the 
torque. Zones 4 and 5 were both formed of conveying elements, and the NS can be injected in 
any one of these zones. The temperatures were set at 120 and 110 °C for zones 4 and 5, 
respectively, to avoid transformation of EFZ from the crystalline to the amorphous state. The 
water of the NS was expected to evaporate rapidly when the NS came into contact with the hot 
barrel and the molten polymer, and the EFZ nanocrystals would remain on the molten polymer. 
However, instant and complete evaporation of water was difficult to achieve, and a back-flow 
phenomenon was observed after NS injection. Therefore, zone 5 was selected for the injection of 
the NS in order to provide more time and space for contact with the molten polymer, and to 
reduce the back-flow of the NS. The 90° mixing elements in zone 2 also assisted in this function. 
This screw configuration forced unevaporated NS to move back and forth between zone 4 and 
zone 5 until complete evaporation of water was achieved. Furthermore, this process would 
increase the contact between NS and the polymer, thus providing better distribution. Mixing 
elements with offset angles of 30° and 60° were used in zone 6. The kneading of these elements 
contributed to the homogeneous distribution of the matrix material. A 90° offset angle was not 
used in these mixing elements in order to avoid the generation and use of too much mechanical 
energy with the EFZ nanocrystals, which may result in the transformation of the crystalline state. 
The temperature for zone 6 and the remaining subsequent zones was set at 130 °C, which would 
further eliminate the remaining water in the matrix material. In zones 7 and 8, 1.0 L/D feed 
screws were used to convey the matrix material to the die. Solidified extrudates coming out of 
the die were milled and processed for further analysis. 
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Figure 2-2. Schematic representation of continuous preparation of a nanocrystal solid dispersion 
using HPH and TSE. 
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Figure 2-3. Screw configuration used in the preparation of nanocrystal solid dispersions by twin-
screw extrusion. 
 
2.4.4. Crystallinity and Morphology of Extrudate 
Differential scanning calorimetry was used to confirm the crystallinity of EFZ after 
extrusion (Figure 2-4). A single sharp endotherm peak was observed for pure EFZ at about 140 
°C (Figure 2-4a), which was identical to that of EFZ form I [118]. Since the drug loading in the 
extrudate was low, the thermograph was magnified, as shown in Figure 2-4b. The endotherm 
peak around 140 °C reappeared in both extrudate A and B. This indicated the EFZ maintained 
crystallinity after the extrusion. 
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Figure 2-4. Evaluation of crystallinity using differential scanning calorimetry. (a) Comparison of 
pure efavirenz, extrudate A (1.02 % drug loading), extrudate B (2.06 % drug loading), and 
Soluplus®. (b) Magnified differential scanning calorimetry thermograph for comparison of 
extrudates A and B. 
 
SEM was used to determine the morphology and distribution of the EFZ particles (Figure 
2-5). Pure EFZ existed as sharp and long needles (Figure 2-5a). The particle size of EFZ was 
around 20 μm. After HPH and HME, the particle size of EFZ was further decreased to less than 
1000 nm. The distribution of EFZ nanocrystals on Soluplus® is quite uniform (Figure 2-5b). The 
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distance between different EFZ nanocrystals prevents them from coming into contact with each 
other and the size consistency will prevent the occurrence of Oswald ripening [122]. These 
features thus establish the conjugated HPH-TSE technique as a novel process to decrease the size 
of EFZ crystals that also aids in the uniform distribution of EFZ nanocrystals. 
 
   
Figure 2-5. Scanning electron microscopy images of (a) pure efavirenz and (b) efavirenz 
nanocrystal solid dispersion (nanocrystals are marked by arrows). 
 
2.4.5. Drug Content and Residual Moisture 
After extrusion, both extrudates were analyzed for drug content. The drug loadings of 
extrudate A and B were around 1.02% and 2.06%, respectively. The drug contents of extrucate A 
and B were 102.47 ± 1.87% and 102.78 ± 4.69%, respectively (Figure 2-6). This indicated that 
all the EFZ in the NS was enveloped in Soluplus®. Considering the low drug loading in the 
extrudates, EFZ nanocrystals were regarded as homogeneously distributed in the extrudates. 
The mean LOD values for the Soluplus® extrudate A, and extrudate B were 2.10, 2.24, 
and 2.26, respectively (Table 2-2), which indicates that there were no significant differences in 
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residual moisture between these three samples (p value > 0.05). Thus, it can be concluded that all 
the water that was added during the process was evaporated. 
 
 
Figure 2-6. Drug content for nanocrystal solid dispersion extrudate A and B. 
 
Table 2-2. LOD for NCSD and Soluplus® extrudates 
Extrudate LOD (%) 
Soluplus® 2.10 ± 0.16 
A 2.24 ± 0.07 
B 2.26 ± 0.12 
                              LOD: loss on drying 
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2.4.6. In Vitro Drug Release 
In vitro drug release was assessed for pure EFZ and both the extrudates (Figure 2-7). As 
the aqueous solubility of EFZ is very low (recorded as 5.26 ± 2.3 μg/mL), 0.2% SLS was added 
to the dissolution media in order to increase the saturation solubility of EFZ, as well as to 
maintain the sink condition. 
Owing to the poor solubility and wettability, only 14.04 ± 0.80% of pure EFZ was 
released after 120 min of dissolution. Both extrudate A and B showed markedly enhanced 
dissolution rates with 96.86 ± 0.99% and 96.20 ± 1.26% drug release overserved for extrudate A 
and B, respectively. It is evident that HPH-TSE successfully increased the dissolution rate. This 
effect could have partially resulted from decreasing the particle size, or from the increase in the 
wettability of EFZ caused by Soluplus®. 
Although the same percentage drug release was reached at 120 min, it was observed that 
the release from extrudate B was slower than that from extrudate A. The difference in the 
dissolution velocity may be because of the different ratios of Soluplus® and EFZ. In extrudate B, 
EFZ was surrounded by a relatively smaller amount of Soluplus® compared to that in extrudate 
A. The different appearances of milled extrudates A and B supported this assumption (Figure 2-
8). In extrudate A, EFZ nanocrystals were completely covered by Soluplus®. Therefore, the 
milled extrudate A was the same yellowish color as the pure Soluplus®. However, the appearance 
of extrudate B was white, which may be because of the uncovered EFZ. This difference will 
result in slower wetting of EFZ, thus decreasing the dissolution velocity of extrudate B. 
However, the differences between these two formulations were not significant. The 
similarity factor (f2) was calculated to determine the similarity between the two formulations. 
The equation used to calculate f2 is:  
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𝑓2 = 50 × 𝑙𝑜𝑔 {[1 + (1 𝑛⁄ ) ∑ (𝑅𝑡 − 𝑇𝑡)
2
𝑛
𝑡=1
]
−0.5
× 100} 
Where Rt and Tt are the dissolution value at time point t of the reference and test product, 
respectively. According to US FDA guidance for industry, two dissolution profiles are 
considered similar when the f2 value is greater than 50 [123]. The calculated f2 value was 55.0, 
which indicated that the two formulations were similar. 
 
 
Figure 2-7. In vitro drug release profiles for pure efavirenz, extrudate A and extrudate B. 
 
   
Figure 2-8. Appearance of milled (a) extrudate A, (b) extrudate B, and (c) Soluplus®. 
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2.4.7. Stability Testing 
Stability testing was conducted for both formulations by storing at 25 °C/60% RH for a 
period of 6 months. At various time points, samples were removed from storage and tested for in 
vitro drug release and micromeritics. 
The release profiles for both the extrudates (A and B) were unchanged over the storage 
period of 6 months (Figure 2-9). The f2 values were calculated versus the initial samples for both 
the extrudates (Table 2-3). All the f2 values were greater than 50, which indicated that the release 
profiles obtained for both the extrudates at each time point were similar to the initial release 
profiles.  
 
Figure 2-9. In vitro release profiles of (a) extrudate A stored at 25 °C/60% relative humidity. 
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Figure 2-9. In vitro release profiles of (b) extrudate B stored at 25 °C/60% relative humidity. 
 
Table 2-3. f2 Values of extrudates with different storage times 
 
f2 
1 month 2 months 3 months 6 months 
Extrudate A 54.5 65.5 66.7 53.8 
Extrudate B 63.9 52.9 58.7 70.7 
 
Comparison of particle size, PDI, and zeta-potential was conducted for the extrudates at 
each time point (Table 2-4). There was no significant change observed at any time point. (P 
value > 0.05). All the above data indicates that the EFZ NCSD prepared by HPH-HME 
technique possesses good stability for a period of 6 months at 25 °C/60% RH. 
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Table 2-4. Comparison of particle size, PDI, and zeta-potential with different storage times. 
Item Time 
Particle Size 
(nm) 
PDI 
Zeta-Potential 
(mV) 
Extrudate A 
Initial 28.04 ± 1.35 0.184 ± 0.03 -16.82 ± 1.21- 
1 Month 28.04 ± 0.17 0.183 ± 0.03 -17.86 ± 1.73 
2 Months 29.78 ± 6.81 0.190 ± 0.04 -17.13 ± 1.32 
3 Months 29.60 ± 4.33 0.179 ± 0.02 -17.26 ± 1.51 
6 Months 29.05 ± 0.26 0.186 ± 0.01 -18.13 ± 5.92 
Extrudate B 
Initial 34.11 ± 5.03 0.193 ± 0.04 -14.38 ± 2.10 
1 Month 30.82 ± 2.78 0.189 ± 0.02 -15.07 ± 1.68 
2 Months 30.67 ± 2.93 0.186 ± 0.03 -14.68 ± 1.52 
3 Months 39.66 ± 5.75 0.185 ± 0.03 -13.75 ± 1.87 
6 Months 32.94 ± 0.88 0.189 ± 0.01 -13.93 ± 0.76 
      PDI: polydispersity index. 
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CHAPTER 3. 
EFFECTS OF PROCESSING ON A SUSTAINED RELEASE FORMULATION 
PREPARED BY TWIN SCREW DRY GRANULATION 
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3.1. Objective 
The objective of this study was to apply twin-screw dry granulation (TSDG) technology 
to produce a sustained-release dry granule formulation, and subsequently compress the sustained 
release tablets. Theophylline was used as a model drug in this research. Design of experiment 
(DoE) was applied in the process to understand the effect of different processing parameters on 
the dry granule properties and optimize these factors. 
 
3.2. Materials 
Theophylline was purchased from Ria International LLC (Saint Louis, MO, US). 
Caffeine citrate was supplied by Fisher Scientific (Pittsburgh, PA, USA). Acetaminophen was 
kindly contributed by Mallinckrodt Inc. (Raleigh, NC, USA). Chlorpheniramine maleate was 
obtained from Medchemexpress LLC (Princeton, NJ, USA). Hydroxypropyl cellulose (KlucelTM 
EF) was generously gifted by Ashland Specialty Ingredients (Wilmington, DE). Ethyl cellulose 
(Ethocel Standard 10) was kindly donated by Dow chemical company. Magnesium stearate was 
purchased from Spectrum Laboratory Products Inc. (Gardena, CA, US). All the other reagents 
used in this study were of the analytical grade. 
 
3.3. Methods 
3.3.1. Preliminary Study 
Four different APIs (Theophylline, Caffeine citrate, Acetaminophen and 
Chlorpheniramine maleate) at three levels of drug loading (30, 40 and 50 %, respectively) were 
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tested for the feasibility of being applied in TSDG. Different formulation parameters, such as 
polymer ratio, lubricant concentration was pretested for their influence on the quality of 
granules. 
 
3.3.2. Design of Experiment 
A Resolution V Irregular Fraction Design was created using Design-Expert® 8.0.6 (Stat-
Ease, Inc., Minneapolis, MN, USA), with three numeric factors (screw speed, feeding rate and 
barrel temperature) and one categorical factor (screw configuration), which all varied over only 
two levels. Flow properties (angle of repose and flowability index), particle size distribution, and 
dissolution time were selected as response variables to optimize the process. 
 
3.3.3. Twin Screw Dry Granulation 
Theophylline was selected as a model drug for this study based on the result of 
preliminary study. All the ingredients were passed through US # 35 mesh screen in order to 
remove any aggregates that might be formed. Theophylline (50% w/w) was premixed with 
KlucelTM EF (25% w/w) and Ethocel (25% w/w) using a MaxiblendTM V-shell blender 
(GlobePharma, New Brunswick, NJ) at 25 rpm for 20 min. Magnesium stearate (0.2% w/w) was 
then added and mixed for 4 min. Dry granulation was prepared using an 11-mm co-rotating twin-
screw extruder (Thermo Fisher Scientific, Waltham, MA, USA) without a die. The extruder 
consists of eight zones, the individual temperature of which, excluding zone 1, can be precisely 
controlled. The barrel was maintained within a temperature range of 70–110 °C. The physical 
mixture was fed into the extruder using an 11-mm single-screw feeder (Thermo Electron, 
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Karlsruhe, Germany) at a selected feeding rate of 3 or 10% (approximately 1.42 or 5.09 g/min). 
The screw speed was set at either 50 or 100 rpm. The materials were collected at the end of the 
extruder after the steady state of was achieved. The collected samples were stored in 
polyethylene bags for further processing and analysis. 
 
3.3.4. Particle size distribution 
The particle size distribution was determined by utilizing the sieve analysis method. The 
granules were divided into three portions by two USA standard test sieve, # 35 (500 µm) and # 
12 (1.68 mm). The large size granules (over 1.68 mm) were retained at the upper sieve (# 12), 
the medium size granules (between 500 µm and 1.68 mm) were retained at the lower sieve (# 
35), the fines (under 500 µm) which were not retained by either sieve were collected by the wax 
paper under the sieves. Each portion of granules were weighed, and the percentile weight 
distribution was calculated accordingly.  
 
3.3.5. Flow Properties 
3.3.5.1. Angle of Repose 
The fixed funnel method was applied to measure Angle of repose. The material was 
poured through a funnel to form a cone. In order to minimize the impact falling particles, the 
height of funnel was gradually elevated to ensure the tip of funnel was held close to the rising 
cone with no touch. Stop pouring the material when the predetermined width of the pile was 
reached. The height and the radius of the base of the cone was measured. The equation to 
calculate the Angle of repose (θ) is as follows: 
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𝑇𝑎𝑛 (𝜃) =  
ℎ
𝑟
 
Where, h is the height of the formed cone and r is the radius of the base of the cone, 
respectively. 
 
3.3.5.2. Flowability Index 
The flowability index was measured using a Flodex powder flowability index test 
instrument (Hanson Research, Chatsworth, CA, USA). The height of funnel was adjusted in the 
way that the funnel bottom was close to but not touching the material surface. 10 g of material 
was poured into the central of the cylinder through the funnel. 30 sec was allowed after loading 
was completed for the possible flocculation of individual material or whole load. 16 mm flow 
disk was used for previously untested material. Slowly turn on the release lever to open the hole 
in the disk without vibration. The test was considered positive when the open hole on the disk 
was observable from the top of cylinder. Repeat tests with disk possessing smaller holes for 
positive results until negative result was achieved. Repeat tests with disk possessing larger holes 
for negative results until positive result was achieved. The smallest hole that the sample could 
fall freely for three successive tests was considered the flowability index [124]. 
 
3.3.6. Differential Scanning Calorimetry 
Approximately 2-5 mg samples of interest were weighed and hermetically sealed in an 
aluminum pan. A Diamond DSC (PerkinElmer, Shelton, CT, USA) was used to measure the 
degree of crystallinity of the samples. The instrument’s Pyris manager software (Shelton, CT, 
39 
USA) was utilized to analyze the data. The heating rate was set at 20 °C/min from 20 to 300 °C 
under an inert atmosphere of nitrogen at a flow rate of 20 mL/min. 
 
3.3.7. Tablet Compression 
200 mg obtained granules were mixed with 0.3% magnesium stearate just prior to manual 
direct compression on a MCTMI single punch tablet press (GlobePharma Inc., New Brunswick, 
NJ, USA). A 0.375 inch flat round punch was used, and a compression force of 150 kg/cm was 
applied. 
 
3.3.8. Scanning Electron Microscopy 
The morphology of all samples (granules, tablets and raw material) was determined by 
utilizing scanning electron microscopy (SEM). Samples was mounted onto an aluminum stage 
by an adhesive carbon tape, and then sputter coated with gold under an argon atmosphere using a 
Hummer 6.2 Sputter Coater (Ladd Research Industries, Williston, VT, US). The coater was kept 
in a high-vacuum evaporator equipped to guarantee a uniform coating. Finally, images were 
captured using a JSM-5600 scanning electron microscope (JEOL USA, Inc., Waterford, VA, US) 
at an accelerating voltage of 5 kV. 
 
3.3.9. In Vitro Drug Release Study 
Both tablets and granules equivalent to 100 mg of theophylline were checked for in-vitro 
drug release. The dissolution media used was 900 mL 0.1 N HCl (pH 1.2, simulated gastric 
medium). SR8-plus™ dissolution apparatus (Hanson, Chatsworth, CA, US) was maintained at 
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37 ± 0.5 °C and the paddle speed was set at 50 rpm. Granules were filled into capsules (size 0) 
for dissolution. The UV spectra were collected by an in-site Rainbow UV-Vis probes (Pion Inc., 
Billerica, MA, USA) at λmax 270 nm every 5 min for first 1 h, then every 15 min until 2 h. 
Tablets were directly dropped into dissolution vessel for test. The UV spectra were collected at 
λmax 270 nm using the same instrument every 15 min for first 1 h and then for every 30 min 
until 24 h. 
 
3.4. Results and Discussion 
3.4.1. Preliminary Study 
3.4.1.1. Lubricant 
While conducting the preliminary study, a grinding noise, which was never found during 
the Hot-Melt Extrusion (HME) process, was heard. This noise indicated the existence of some 
friction in the twin screw extruder. In HME, the flexible nature of melt will not cause any 
rubbing at powder-instrument interfaces (wall friction) [125]. The lubrication effect of the melt 
itself will also prevent the abrasion between the screw and barrel. However, in the TSDG 
process, all materials were kept in solid state, friction could occur universally where the contact 
of equipment and material occurred. Thus, addition of dry lubricant was necessary to both 
protect the instrument and prevent the contamination of products. Magnesium stearate, which 
was widely used dry lubricants in the pharmaceutical industry, was applied to the formulation. It 
was found that magnesium stearate was able to eliminate the noise mentioned above. 
Nevertheless, too much amount of magnesium stearate may significantly decrease the yield of 
granule, even results in entire fines. This phenomenon was resulted from the nature of lubrication 
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effect. The lubricant molecules will form some oriented monolayer or multilayer boundary, 
which will prevent the additional contact between instruments and powder particles. However, 
too much lubricant or long time mixing with API and excipients will results in the boundary 
formed between particles, thus prevention of agglomeration of powder particles. In this case, a 
moderate quantity of 0.2% magnesium was selected and added to the formulation at the final 
stage of mixing. 
 
3.4.1.2. Polymer and Excipient Ratio 
Hydroxypropyl cellulose (HPC), which is a thermoplastic polymer, has been previously 
studied as dry binders for both tablet compression [126-128] and roller compaction [129]. 
Ethylcellulose (EC), which is a water-insoluble polymer has applied to prepare lots of sustained 
release formulation [130-132]. Thus, the combination of HPC (dry binder) and EC (release 
controller) was selected for the excipients for preparation of sustained release dry granulation. 
Two ratios of EC and HPC (1:1 and 3:1) were studied to optimize the blend of polymers. The 1:1 
combination exhibited a better probability to produce medium size granule. Therefore, 1:1 ratio 
of EC and HPC was used as excipients for this study. 
 
3.4.1.3. API and Drug Loading 
Four different APIs (Chlorpheniramine maleate, Acetaminophen, Caffeine citrate and 
Theophylline) with a broad melting point range from 140 °C to 270 °C were selected as 
candidates for TSDG process. Physical mixture with each API at three drug loadings (30, 40 and 
50%, respectively) was prepared for the test of feasibility to be applied in TSDG (Table 3-1). All 
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the tests were conducted at same feeding rate, screw speed, screw configuration and barrel 
temperature. 
 
Table 3-1. Candidate of APIs. 
No. Drug name BCS 
MP Literature 
/Measurement 
1 
Chlorpheniramine 
maleate 
I 142/139.26 °C 
2 Acetaminophen I 169/172.7 °C 
3 Caffeine Citrate I 
235.6 - 
236.2/168.69 °C 
4 Theophylline I 273/276.77 °C 
 
Each product after TSDG was tested with DSC to detect the crystallinity of API (Figure 3-
1). All the DSC thermograms showed a single sharp endotherm peak, which demonstrated the 
preservation of the crystallinity after TSDG. 
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Figure 3-1. DSC thermograms of four API and products after TSDG. Formulation A: 30 % drug 
loading, formulation B: 40% drug loading, C: 50% drug loading. 
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Figure 3-1. DSC thermograms of four API and products after TSDG. Formulation A: 30 % drug 
loading, formulation B: 40 % drug loading, C: 50 % drug loading. 
 
The morphology of products obtained was summarized in Table 3-2. It was obvious that 
the low drug loading PM tended to achieve more robust and greater size granule after TSDG. 
However, none of these four APIs could form granule at high drug loading of 50%. That’s 
because more binder was presented in the low drug loading formulation. The higher binder ratio 
could more effectively assisted the agglomeration of raw materials, thus granulation. Due to the 
low ratio of binder in the 50% formulation, the raw material could not accumulate together to 
form granules, hence presented as fine powders. From the API aspect, Acetaminophen and 
Caffeine citrate showed the best ability to be granulated. More sturdy and bigger size granules 
were attained at 30% drug loading. On the contrary, 30% of chlorpheniramine maleate and 
theophylline could only achieve smaller and long strip shape granule. The theophylline granule is 
even weaker than the chlorpheniramine maleate granule. For the 40% drug loading, 
Acetaminophen and Caffeine citrate still can form some long striped shape granule. However, 
barely any granule could be seen from the chlorpheniramine maleate and theophylline 
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formulation. In summary, higher drug loading will hinder the formation of granulation. And 
theophylline was the most difficult one to be granulated among these four APIs. If dry 
granulation could be accomplished for the most difficult formulation combination, it could be 
much easier for another recipe. Therefore 50% drug loading of theophylline was designated for 
the DoE study of processing parameters optimization. 
 
Table 3-2. Morphology of 4 APIs at 3 different drug loading after TSDG. 
 30% 40% 50% 
Chlorpheniramine 
maleate 
   
Acetaminophen 
   
Caffeine Citrate 
   
Theophylline 
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3.4.2. DoE Set up 
Other than the formulation parameters, processing parameters are also critical to the final 
product quality. To determine the appropriate ranges of experimental design, a series of 
processing parameters were tested. From these initial results, four processing parameters (screw 
configuration, screw speed, barrel temperature and feeding rate) were selected and the operation 
ranges were shown in Table 3-3. Two screw configurations utilized in the experimental design 
were shown in Figure 3-2. For screw configuration 1, only one mixing zone, which was 
comprised of 7 mixing elements with 60° offset angles, was presented at zone 5. For screw 
configuration 2, another small mixing zone, which was comprised of 5 mixing elements with 30° 
offset angles, was added at zone 7. The barrel temperature profile was shown in Table 3-4. The 
highest temperature was set at zone 5 to assist the granulation process. 
 
 
Figure 3-2. Screw configuration utilized in TSDG. 
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Table 3-3. Experimental factors and ranges of variation. 
Type 
Independent Variable 
(Factor) 
Symbol Unit 
Upper 
Level (+1) 
Lower 
Level (-1) 
Categorical Screw Configuration A N/A 
Two 
Mixing 
Zone 
One 
Mixing 
Zone 
Numeric 
Barrel Temperature (Zone 5) B oC 110 90 
Screw Speed C Rpm 100 50 
Feeding Rate D % 10 3 
 
Table 3-4. Barrel Temperature Setting. 
 
Zone 8 Zone 7 Zone 6 Zone 5 Zone 4 Zone 3 Zone 2 
oC 
Temperature 
(-1) 
70 70 80 90 80 70 70 
Temperature 
(+1) 
90 90 100 110 100 90 90 
 
Twelve runs of experimental design were proposed using a Resolution V Irregular 
Fraction Design (Table 3-5). This experimental design was selected because it would allow of 
estimation of all main effects. The two-factor interactions will be aliased only by three-factor or 
higher interactions [133]. This design was considered as an excellent design, which was a 
worthwhile alternative to the full factorial design, to reduce the number of runs and still obtain 
clean results. 
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Table 3-5. Experimental Design. 
Std Run A B C D 
2 1 +1 110.00 50.00 3.00 
4 2 +1 90.00 100.00 3.00 
12 3 -1 110.00 100.00 10.00 
5 4 -1 110.00 100.00 3.00 
1 5 -1 90.00 50.00 3.00 
8 6 +1 90.00 50.00 10.00 
7 7 -1 90.00 50.00 10.00 
9 8 -1 110.00 50.00 10.00 
11 9 +1 90.00 100.00 10.00 
6 10 +1 110.00 100.00 3.00 
10 11 +1 110.00 50.00 10.00 
3 12 -1 90.00 100.00 3.00 
 
3.4.3. Characterization of crystallinity 
Theophylline was categorized as a Biopharmaceutics Classification System (BCS) I drug. 
Thus the crystallinity of theophylline was expected to be maintained in order to prevent the 
potential thermal stability problem [134]. The crystallinity of theophylline as pure drug and in all 
twelve runs was confirmed by utilizing DSC (Figure 3-3). A single sharp endotherm peak at 
around 275 oC, as well as a small endotherm peak at about 288 oC, was observed for pure 
theophylline. This demonstrated the API we used was belong to the theophylline anhydrous form 
I [59, 135]. After TSDG, the big endotherm peaks of all runs were preserved, however it was 
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compressed to around 270 oC. In the meantime, the small endotherm peak also shifted a little bit 
to lower temperature. These results confirmed that the crystallinity of theophylline was preserved 
after TSDG, Nevertheless, some interaction between theophylline and polymers was likely to 
occur [136]. 
 
 
Figure 3-3. DSC thermograms. 
 
3.4.4. The effects of the processing parameters on the particle size distribution 
Each run of samples was separated into three portions: the large size granules (over 1.68 
mm), the medium size granules (between 500 µm and 1.68 mm) and the fines (under 500 µm). 
The granule size distribution results for all runs were shown in Table 3-6. The medium size 
granules are the most important part for the tableting process. In addition, fines are also very 
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important to the compression and compaction features, since the vacant space between granules 
could be occupied by them. However, the amount of fines should not be over 10% [137]. It was 
also mentioned that a small amount of fines could improve the appearance of tablet [87]. Thus, 
both the medium size granule and fines were selected as dependent variable (response) in the 
Resolution V Irregular Fraction Design. The regression equations for both medium size granules 
and fines fraction were calculated from the experimental results. The coefficients and the 
statistical significance were summarized in Table 3-7. It should be mentioned that only the 
parameters related to independent variables (factors) and models were given. The full regression 
equation was shown under each section. 
 
Table 3-6. DoE Results. 
Run 
Fines (< 
500µm)/% 
Medium 
Size Granule 
(500 µm - 
1.68 mm)/% 
Large Size 
Granule 
(> 1.68 
mm)/% 
Angle of 
Repose/o 
Flowability 
Index/mm 
Dissolution Time 
for Maximum 
Drug Release/h 
1 2.69 32.29 65.02 28.92 20 13 
2 74.63 25.37 0 31.23 22 23 
3 6.88 70.42 22.7 27.6 14 16 
4 13.74 59.23 27.03 30.65 24 12 
5 25.24 56.15 18.61 27.02 20 23 
6 12.41 51.49 36.1 26.67 22 16 
7 12.46 64.76 22.78 25.49 9 15 
8 4.98 53.84 41.18 26.93 14 10 
9 29.39 57.93 12.68 29.18 20 18 
10 23.71 66.98 9.31 28.48 22 20 
11 0.61 11.45 87.94 30.14 34 16 
12 30.36 59.43 10.21 29.24 20 21 
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Table 3-7. Statistical analysis and regression coefficients of the particle size distribution. 
Variables 
Angle of repose 1/√𝐹𝑙𝑜𝑤𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑖𝑛𝑑𝑒𝑥 
Coefficient P Coefficient P 
Model  0.0332  0.0007 
Intercept 28.01  0.23  
A 0.42 0.1032 -0.027 0.0003 
B 0.50 0.0697 -0.016 0.0006 
C 0.75 0.0248 0.000 1.0000 
D -0.54 0.0567 0.016 0.0007 
 
R2 = 0.9694 
Pred R2 = 0.5107 
R2 = 0.9998 
Pred R2 = 0.9936 
 
3.4.4.1. Medium size granules 
The percentage of medium size granules in all 12 runs varied in a wide range of 11.45 – 
70.42%, where run 1, 2 and 11 showed the least medium size granule yield (less than 35%), and 
run 3,7 and 10 could achieve the highest amount of medium size granule (Over 60%). The 
regression  equation for the percentage of medium size granules was created as follows: 
% 𝐌𝐞𝐝𝐢𝐮𝐦 𝐬𝐢𝐳𝐞 𝐠𝐫𝐚𝐧𝐮𝐥𝐞
= +𝟓𝟔. 𝟎𝟕 − 𝟏𝟎. 𝟐𝟓 ∗ 𝐀 − 𝟎. 𝟔𝟗 ∗ 𝐁 + 𝟔. 𝟖𝟑 ∗ 𝐂 + 𝟑. 𝟏𝟓 ∗ 𝐃 + 𝟑. 𝟏𝟔 ∗ 𝐀 ∗ 𝐂
+  𝟓. 𝟏𝟗 ∗  𝐁 ∗  𝐂 −  𝟔. 𝟑𝟓 ∗  𝐁 ∗  𝐃 +  𝟕. 𝟎𝟎 ∗  𝐂 ∗  𝐃 +  𝟖. 𝟖𝟕 ∗  𝐀 ∗  𝐁 ∗  𝐂 
Based on the ANOVA analysis, the p value of the model was 0.0347, which indicated the 
model was reliable. The most significant factors for the percentage of medium size granule was 
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found to be screw configuration and screw speed. The relationship between the response and 
these two factors could be better understood by the contour plot shown in Figure 4. Figure 3-4a 
and 3-4b were both obtained at the feeding rate of 10%. The only difference was the screw 
configuration: one mixing zone for Figure 4a and two mixing zones for Figure 3-4b. 
 
  
                                             a                                                                              b 
Figure 3-4. Contour plots showing the effect of screw speed on percentage of medium size 
granules (a) one mixing zone configuration, (b) two mixing zone configuration. 
 
It was obvious that the Figure 3-4a showed more medium size granule than Figure 3-4b, 
which meant the one mixing zone configuration is beneficial for the generation of this mid-size 
portion particles. This result was in accordance with the negative coefficient (-10.25) in front of 
A. This phenomenon could be explained by the effect of the second mixing zone. It was reported 
by Dhenge et al. that the second mixing zone could either decrease or increase the size of 
agglomerated granule by the first mixing zone. This size alteration was owing to several 
functions of the second mixing zone: shearing, deformation, breaking, mixing, re-granulation 
and consolidation [138]. In our circumstances, if the granule generated by the first mixing zone 
was not strong enough, it could be broken down into smaller granule or fines. On the contrary, if 
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the previously obtained granule had adequate strength, it would be further combined to form 
bigger granule. In either situation, the amount of medium size granule would decrease. Hence the 
second mixing zone was considered as a hindrance of the medium size granule. 
Both Figure 3-4a and 3-4b showed the same tendency that the increased screw speed 
would lead to higher percentage of medium size granule. At first glance, it seemed to conflict 
with the data of Tu et al., who claimed the increasing screw speed would decrease the granule 
size[139]. However, it was same when the large size granule was taken into consideration as 
well. From the regression equation of large size granule (data not shown), the negative 
correlation was found between large size granule amount and screw speed. Hence it could be 
roughly equivalent to the condition, which the increased screw speed would cause the decrease 
of large size granule and increase of medium size granule, i.e., decrease the whole granule size. 
The possible mechanism should be the mean residence time decreases with increasing screw 
speed, resulting in less kneading effect on powder particles, thus generating smaller granules. 
 
3.4.4.2. Fines 
The fines amount also varied largely among 12 experimental design (0.61 – 74.63%). 
Similar to medium size granules quantity, the regression equation was also given for percentage 
of fines. However, based on the Box-Cox Plot, it was recommended by the software to do the 
square root transformation for the response, which was presented as  y’ =  √𝑦 + 𝑘, k = 0 in this 
case. Hence the new regression equation was shown as follows: 
√% 𝐅𝐢𝐧𝐞𝐬 = +𝟑. 𝟗𝟔 + 𝟎. 𝟏𝟗 ∗ 𝐀 − 𝟏. 𝟏𝟏 ∗ 𝐁 + 𝟎. 𝟕𝟓 ∗ 𝐂 − 𝟎. 𝟖𝟑 ∗ 𝐃 − 𝟎. 𝟒𝟑 ∗ 𝐀 ∗ 𝐁 + 𝟎. 𝟔𝟐
∗ 𝐀 ∗ 𝐂 
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The p value of 0.0018 was a visible sign that the model was dependable. Based on the 
significant effect (Table 3-7), barrel temperature, screw speed and feeding rate all had significant 
effect on fines amount (p < 0.05). The regression results could be visually assessed by the 
contour plot as shown in Figure. 5. 
Figure 3-5a and 3-5b was gained under screw speed of 100 rpm with two different screw 
configuration. Negative correlation could be found for percentage of fines with barrel 
temperature and feeding rate. The decrease of fines could also be thought as the increase of 
granulated particles. Therefore, this phenomenon was transformed to the situation that higher 
feeding rate and barrel temperature would lead to more granules. Osborne et al. [140] and Palzer 
et al. [141] both stated the contact points between powder particles might sinter together to form 
solid bridges when the temperature was increased to close the the glass transition temperature. 
The solid bridge would bond the particles together to form strong agglomerates, i.e. granules. In 
this case, the increased temperature would support the formation of granules. The same 
relationship between granule and feeding rate was also observed by a lot of authors [19, 142, 
143]. Higher feeding rate would cause more powder in the barrel, thus easier for them to be 
condensed and compacted into granules. 
Unlike the two factors mentioned above, screw speed positively affect the percentage of 
fines (Figure 3-5c and 3-5d). This effect could be easily explained by the mechanism mentioned 
in the medium size granule part. The increased screw speed would decrease the particle size, thus 
generating more fine particles. 
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                                     a                                                                    b 
 
                                    c                                                                     d 
Figure 3-5. Contour plots showing the effect of barrel temperature, screw speed and feeding rate 
on percentage of fines: (a) & (c) one mixing zone configuration, (b) & (d) two mixing zone 
configuration. 
 
3.4.5. The effects of the processing parameters on the flow property 
One of the most important objectives of granulation was to improve the flow property of 
raw materials. This increased flow property could have numerous advantages, such as consistent 
tablet properties, more uniformed formulation and high production speed. Therefore, the 
assessment of flow property of granule became a very important step to examine the effect of 
granulation operation. Angle of repose was the most widely used method to determine the flow 
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property. However, it was also mentioned the data obtained from angle of repose was not a 
dependable because this method did not mimic the powder’s behavior in the instrument [124]. 
To solve this problem, another technique called flowability index was developed to characterize 
the flow property. In this study, both methods were utilized to test the flow property of samples. 
The data gained was further apply to experimental design to obtain the regression equation. The 
coefficients and the statistical significance were summarized in Table 3-8. 
 
Table 3-8. Statistical analysis and regression coefficients of the flow property. 
Variables 
Angle of repose 1/√𝐹𝑙𝑜𝑤𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑖𝑛𝑑𝑒𝑥 
Coefficient P Coefficient P 
Model N/A 0.0332 N/A 0.0007 
Intercept 28.01 N/A 0.23 N/A 
A 0.42 0.1032 -0.027 0.0003 
B 0.50 0.0697 -0.016 0.0006 
C 0.75 0.0248 0.000 1.0000 
D -0.54 0.0567 0.016 0.0007 
 
R2 = 0.9694 
Pred R2 = 0.5107 
R2 = 0.9998 
Pred R2 = 0.9936 
 
3.4.5.1. Angle of repose 
The angle of repose for samples of 12 runs dispersed in a very narrow range. Other than 
run 2, 4 and 11, all runs shows excellent flow property (25o < angle of repose < 30o). The 
resultant regression equation was created as follows: 
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𝐀𝐧𝐠𝐥𝐞 𝐨𝐟 𝐫𝐞𝐩𝐨𝐬𝐞
= +𝟐𝟖. 𝟎𝟏 + 𝟎. 𝟒𝟐 ∗ 𝐀 + 𝟎. 𝟓𝟎 ∗ 𝐁 + 𝟎. 𝟕𝟓 ∗ 𝐂 − 𝟎. 𝟓𝟒 ∗ 𝐃 + 𝟎. 𝟓𝟐 ∗ 𝐀 ∗ 𝐃
− 𝟎. 𝟔𝟕 ∗ 𝐁 ∗ 𝐂 − 𝟎. 𝟔𝟎 ∗ 𝐂 ∗ 𝐃 − 𝟎. 𝟕𝟕 ∗ 𝐀 ∗ 𝐁 ∗ 𝐂 
The p-value was given as 0.0332, which demonstrated the model was reliable. Screw 
speed showed the most significant effect on angle repose (p < 0.05). However, the effect of 
barrel temperature and feeding rate were also not negligible (p < 0.10). 
The positive coefficient for screw speed implied the increase of screw speed would cause 
the high angle of repose, which represented the low flow property. While the feeding rate 
exhibited a negative coefficient, which meant the higher feeding rate would lead to lower angle 
of repose and better flow property. Both of these parameters corresponded with the fins amount 
very well. Increasing screw speed or decreasing feeding rate would result in more fines, leading 
to poorer flow property and higher angle of repose. Nevertheless, the positive constant in front of 
barrel temperature, which represented higher temperature would increase angle of repose and 
decrease flow property of granules, seemed to be conflict with data achieved from the percentage 
of fines. This could be explained by the granule shape. In spite of particle size, particle shape 
was also quite a critical parameter to affect the flow property. It was observed the granule 
produced in higher temperature would be more tend to be in a long stripe shape, which was 
definitely had poor flow property. The effect of aforementioned parameters on angle of repose 
was plotted into contour as showing in Figure 3-6. 
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                                           a                                                                            b 
 
                                           c                                                                             d 
Figure 3-6. Contour plots showing the effect of barrel temperature, screw speed and feeding rate 
on angle of repose: (a) & (c) one mixing zone configuration, (b) & (d) two mixing zone 
configuration. 
 
3.4.5.2. Flowability Index 
The flowability index was defined as the smallest hole through which the core cylinder of 
powder could overcomes the side internal friction and pass. Based on this definition, flowability 
index was similar to angle of repose: higher number presented lower flow property. It was 
mentioned a good range of flowability index was l0–24 mm [124]. For this parameter, an inverse 
square root transformation was suggested by the software, resulting in the regression equation as: 
59 
𝟏
√𝑭𝒍𝒐𝒘𝒂𝒃𝒊𝒍𝒊𝒕𝒚 𝒊𝒏𝒅𝒆𝒙
= +𝟎. 𝟐𝟑 − 𝟎. 𝟎𝟐𝟕 ∗ 𝑨 − 𝟎. 𝟎𝟏𝟔 ∗ 𝑩 + 𝟎. 𝟎𝟏𝟔 ∗ 𝑫 + 𝟓. 𝟒𝟖𝟐𝒆 − 𝟎𝟎𝟑 ∗ 𝑨 ∗ 𝑩
− 𝟎. 𝟎𝟐𝟕 ∗ 𝑨 ∗ 𝑫 − 𝟐. 𝟔𝟎𝟐𝒆 − 𝟎𝟎𝟑 ∗ 𝑩 ∗ 𝑪 − 𝟎. 𝟎𝟏𝟒 ∗ 𝑩 ∗ 𝑫 + 𝟐. 𝟐𝟗𝟔𝒆 − 𝟎𝟎𝟑
∗ 𝑪 ∗ 𝑫 
This model accompanied with a p-value of 0.007 implied its high confidence level. Screw 
configuration, barrel temperature and feeding rate were found to have significant effect on 
flowability index. However, the complicated transformation did make the relationship between 
different factors unclear. Hence it is best to look into the contour plot to better understand the 
effect of different factors (Figure 3-7). 
When looking into Figure 3-7a (one mixing zone), it was found higher temperature and 
lower feeding rate would result in higher flowability index, thus poorer flow property. This result 
was the same with the angle of repose. In Figure 7b, the effect of barrel temperature was still the 
same. Interestingly, the effect feeding rate showed different effect at different conditions. When 
barrel temperature was below 95 oC, feeding rate barely had any effect on flowability index. This 
was because the ability of higher feeding rate to decrease fines was offset by the second mixing 
zone. However, when the temperature was over 95 oC, higher feeding rate was more tend to 
increase the portion of large size granule, thus lead to higher flowability index. When comparing 
Figure 3-7a and 3-7b, it was found the granules produced with two mixing zone configuration 
would have less flow property, which correlate with the fact the second mixing zone will create 
more fines or large size granules. 
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                                           a                                                                           b 
Figure 3-7. Contour plots showing the effect of barrel temperature and feeding rate on 
percentage of medium size granules (a) one mixing zone configuration, (b) two mixing zone 
configuration. 
 
3.4.6. In-vitro drug release study 
The simulated gastric solution (0.1 N HCl, pH = 1.2) was utilized in the dissolution study 
as dissolution medium. Ten runs of samples released more than 95% drug in 23 hours (Run 2 and 
Run 5 > 94%). The maximum drug release time for tablets varied from 10 to 23 hours (Figure 3-
8 and Table 3-6). The regression equation suggested by Design Expert software was shown as 
follows: 
𝐃𝐢𝐬𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐓𝐢𝐦𝐞
= +𝟏𝟔. 𝟗𝟐 + 𝟐. 𝟏𝟑 ∗ 𝐀 − 𝟐. 𝟒𝟐 ∗ 𝐁 + 𝟏. 𝟔𝟐 ∗ 𝐂 − 𝟎. 𝟕𝟓 ∗ 𝐃 + 𝟏. 𝟑𝟕 ∗ 𝐀 ∗ 𝐁
+ 𝟏. 𝟔𝟑 ∗ 𝐁 ∗ 𝐂 + 𝟐. 𝟓𝟎 ∗ 𝐁 ∗ 𝐃 
The p-value provided for this model was 0.0056 (Table 3-9), Three factors (screw 
configuration, barrel temperature and screw speed) were discovered to have significant effect on 
dissolution time. The positive coefficient of screw configuration and screw speed implied that 
when two mixing zone configuration and high screw speed were applied, the dissolution time of 
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tablet would increase, that was slower release. However, when the higher temperature was 
utilized, the release would be faster. Actually, this result was totally opposite to what have been 
expected, which was based on the granule properties mentioned above. The only explanation 
could be the tableting process had done some change to the granule property.  
 
Table 3-9. Dissolution time statistical analysis and coefficients of regression. 
Variables 
Dissolution time for maximum drug release (h) 
Coefficient P 
Model  0.0056 
Intercept 16.92  
A 2.12 0.0065 
B -2.42 0.0019 
C 1.62 0.0164 
D -0.75 0.1401 
 
R2 = 0.9726 
Pred R2 = 0.7537 
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Figure 3-8. In-vitro release profiles of a tablets from 12 runs of samples. 
 
To confirm the aforementioned assumption, the dissolution of primary granules was 
conducted as well. The time for 80% drug release of both tablets and granules were compared. 
80% percent drug release was selected because the release time for different runs of samples at 
this level showed enough distinction degree. The result was summarized in Table 3-10. It was 
quite noticeable that the dissolution time could be divided into two groups. In addition, the 
release time for tablet and granule from same run of experiment was opposite. In detail, 
counterpart (capsule) of fast release tablet will release slow, vice versa. 
This negative correlation of tablet and capsule release time was quite interesting. The 
principle under this phenomenon could be explained by the effect of binder. When the big size or 
strong granule was formed (these two parameters usually have positive correlation based on our 
observation), which release relatively slow, more binder in the formulation would be occupied in 
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the granule. The binder outside of granule would be in small amount. In this case, when the 
tablet was compressed, the binder to connect granules together would not be enough, which 
meant the adhesion of granules would be weak. The tablet would be more easily to disintegrated 
into granules, and release faster because of the enhanced surface area. This hypothesis was 
supported by the SEM photograph taken for granules and tablets (Figure 3-9). All the images 
were taken at 25 times magnification. As can be seen from the picture, from run 11 to run 2, the 
granule size decreased gradually, simultaneously, the diminution of cleavage on the counterpart 
tablet was apparent. The cleavage was a very clear sign of the weak adhesion among granules. 
Thus, the hypothesis should be reasonable. 
 
   
                                         a                                                                          b 
   
                                         c                                                                           d 
Figure 3-9. SEM photograph of granules and tablets: (a) & (b) Run 11, (c) & (d) Run 3 
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                                        e                                                                                f 
Figure 3-9. SEM photograph of granules and tablets: (e) & (f) Run 2. 
 
Table 3-10. 80% drug release time for tablet and capsule. 
 
Tablet (h) Capsule (min) 
F1 3.2 
Release Time < 4 
h 
25 
Release Time > 
15 min 
F3 3.1 15 
F7 2.5 25 
F8 2.9 17.5 
F11 3.8 29 
F2 6.9 
Release Time > 4 
h 
7 
Release Time < 
15 min 
F4 4.5 14 
F5 6 7 
F6 4.7 13 
F9 4.5 9 
F10 6.3 10 
F12 7 14 
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3.4.7. Optimization of processing parameters 
From a serial of experiments, the relationship between different factors and responses 
was quite clear. However, it was too complicated to analyze them together (Table 3-11). What’s 
worse, some of the parameters required by different responses conflict with each other. For 
example, less amounts of fines and larger quantity of medium size granules were both preferred, 
but screw speed have opposite effect on these two responses. Therefore, a sophisticated model to 
optimize the factors was necessary. Luckily enough, all the models we obtained from the 
software had high R2 and pred R2, which guaranteed the possibility of utilizing these models to 
do the optimization. Based on the previous description and experiment data, the goal was set as, 
fines (5-10%), Medium size granules (60-80%), Angle of repose (25-30o), Flowability index (10-
24 mm), Dissolution time (12-16 h). The desirability plot was given in Figure 3-10. The 
conclusion could be drawn was high feeding rate and screw speed should be utilized. Relatively 
low barrel temperature was beneficial for the goal. Only one mixing zone configuration should 
be applied. 
 
Table 3-11. Summarization of relationship between factors and responses. 
 % Fines 
% Medium 
size 
granules 
Angle of 
repose 
Flowability 
index 
Release 
time 
Screw 
configuration 
N/A - N/A + + 
Barrel 
temperature 
- N/A + + - 
Screw speed + + + N/A + 
Feeding rate - N/A - - N/A 
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Figure 3-10. Desirability plot of set goals. 
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CHAPTER 4. 
COMPARISON OF DRUG RELEASE FROM KOLLIDON® SR MATRICES 
PREPARED BY A DIRECT COMPRESSION METHOD AND TWIN SCREW 
EXTRUSION TECHNOLOGY 
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4.1. Objective 
The major objective of the present project was to produce sustained-release tablets by 
both direct compression and HME technique. The physicochemical properties of both products 
were analyzed to determine the drug release mechanism. Theophylline (Figure 4-1) was chosen 
for this study for two reasons. Firstly, theophylline was a Biopharmaceutics Classification 
System (BCS) class I drug, which means it has high solubility and permeability. This property 
will make the observation of the sustained release effect easier. Secondly, the melting of 
theophylline is over 270 oC, which can effectively prevent the unexpected API transformation 
from crystalline to amorphous state in HME. Because this conversion may interrupt the analysis 
about effects of two techniques. 
 
 
Figure 4-1. Chemical structure of theophylline. 
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4.2. Materials 
Theophylline was purchased from Ria International LLC (Saint Louis, MO, US). 
Kollidon® SR was generously gifted by BASF SE (Ludwigshafen, Germany). Magnesium 
stearate was purchased from Spectrum Laboratory Products Inc. (Gardena, CA, US). Food Color, 
Blue (Liquid) was purchased from PCCATM (Houston, TX, US). All the other reagents used in 
this study were of the analytical grade. 
 
4.3. Methods 
4.3.1. Twin Screw Extrusion 
All the ingredients were passed through US # 35 (500 µm) mesh screen, in order to 
remove any aggregates that might be formed. Theophylline (30% w/w) was premixed with 
Kollidon® SR (70% w/w) using a MaxiblendTM V-shell blender (GlobePharma, New Brunswick, 
NJ) at 25 rpm for 20 min. These binary physical mixtures (PM) were extruded using a HAAKE 
MiniLab II counter-rotating twin screw extruder (Thermo Fisher Scientific, Waltham, MA, USA) 
at a screw speed of 100 rpm and barrel temperature of 100 °C to obtain resultant extrudates 
(Ext). The Ext were collected at the end of the extruder after the steady state of was achieved. 
Half of the Ext were milled and passed through USA standard sieve # 35 to achieve Milled 
Extrudates (ExtM). Either Ext or ExtM were stored separately in polyethylene bags for further 
processing and analysis. 
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4.3.2. Differential Scanning Calorimetry 
Approximately 2-5 mg samples of interest were weighed and hermetically sealed in an 
aluminum pan. A Diamond DSC (PerkinElmer, Shelton, CT, USA) was used to measure the 
degree of crystallinity of the samples. The instrument’s Pyris manager software (Shelton, CT, 
USA) was utilized to analyze the data. The heating rate was set at 20 °C/min from 20 to 300 °C 
under an inert atmosphere of nitrogen at a flow rate of 20 mL/min. 
 
4.3.3. Tablet Compression 
100 mg obtained PM or ExtM were mixed with 0.3% magnesium stearate just prior to 
manual direct compression on a MCTMI single punch tablet press (GlobePharma Inc., New 
Brunswick, NJ, USA). An 8 mm flat round punch was used, and a compression force of 120 
kg/cm was applied. 
 
4.3.4. In Vitro Drug Release Study 
The compressed ExtM tablets (ExtT), direct compressed tablets (DCT), theophylline, Ext, 
PM, ExtM equivalent to 30 mg of theophylline were evaluated for in-vitro drug release. The 
dissolution media used was 900 mL 0.1 N HCl (pH 1.2, simulated gastric medium). SR8-plus™ 
dissolution apparatus (Hanson, Chatsworth, CA, US) was maintained at 37 ± 0.5 °C and the 
paddle speed was set at 50 rpm. PM and ExtM were filled into capsules (size 0) for dissolution. 
Tablets and Ext were directly dropped into dissolution vessel for test. Samples were collected at 
intervals of 1/6, 1/2, 1, 2, 4, 8, 12 and 24 h through a stainless-steel cannula with a 0.2-μm nylon 
filter tip attached to a 2.5-mL syringe. The samples were analyzed directly using a GENESYS 6 
71 
UV–vis spectrophotometer (Thermo Scientific, Madison, WI, US) at a wavelength of 270 nm. 
The standard curve was linear over the range of 1–50 μg/mL with an R2 equal to 0.9996. 
 
4.3.5. Scanning Electron Microscopy 
The surface morphology of all samples (theophylline, Kollidon® SR, Ext, ExtT, DCT) 
and interior structure of tablets (ExtT and DCT) were determined by utilizing scanning electron 
microscopy (SEM). Samples was mounted onto an aluminum stage by an adhesive carbon tape, 
and then sputter coated with gold under an argon atmosphere using a Hummer 6.2 Sputter Coater 
(Ladd Research Industries, Williston, VT, US). The coater was kept in a high-vacuum evaporator 
equipped to guarantee a uniform coating. Finally, images were captured using a JSM-5600 
scanning electron microscope (JEOL USA, Inc., Waterford, VA, US) at an accelerating voltage 
of 5 kV. 
 
4.3.6. Dynamic Vapor Sorption 
The water sorption behavior of API, polymer, tablets, milled and primary extrudates were 
determined by Intrinsic DVS (Surface measurement systems, London, UK). 20 ± 0.5 mg samples 
were exposed to the controlled relative humidity profile (0-100-0%) at a constant temperature 
(37 °C), and the weight changes were measured by a CahnD200 ultra-microbalance (±0.01 mg 
mass resolution). The dm/dt mode was used in all the steps, and the limitation was set at 0.01 
%/min to detect the equilibrium (the instrument would start next step when the samples dm/dt 
value equal or less than 0.001%/min). At first step, sample was dried at 0% RH, and the 
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equilibrated mass at 0% RH was used as reference mass. The water sorption isotherms were 
calculated using the equilibrated sample mass from each step [144]. 
 
4.3.7. Water Sorption Pathway 
2 mL of food color was uniformly mixed with the 898 mL above mentioned dissolution 
media in the in vitro drug release study section. All dissolution apparatus and parameters were 
set identically as the in vitro drug release study. Tablets were directly dropped into dissolution 
vessel for test. Soaked tablets were removed from the dissolution media at intervals of 1, 2, 4, 8, 
12 and 24 h. The outside surface of tablets was dried quickly utilizing paper towels. The tablets 
were then evenly split into two parts. The cross sections of each tablets were photographed for 
comparison. 
 
4.4. Results and Discussion 
4.4.1. Characterization of Crystallinity 
The crystallinity of theophylline as pure drug and in ExtM and PM was confirmed by 
utilizing DSC (Figure 4-2). A single sharp endotherm peak at around 275 oC was observed for 
pure theophylline. This demonstrated the API we used was belong to the theophylline anhydrous 
form I [135]. After HME, the endotherm peak could still be seen from the DSC thermogram, 
however it was compressed to around 255 oC. These results confirmed that the crystallinity of 
theophylline was preserved after HME. Nevertheless, some interaction between theophylline and 
Kollidon® SR was likely to occur [136]. 
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Figure 4-2. DSC thermograms of theophylline, Kollidon® SR, PM and ExtM. 
 
4.4.2. In-vitro Drug Release 
The release profile of all samples was summarized in Figure 4-3. Obviously, the pure 
theophylline achieved the fastest release rate, owing to its high solubility. More than 95% of 
drug was released in just 30 min, and full drug release was attained in the dissolution period. The 
release of PM was quite similar to that of theophylline, while a little bit slower. 95% drug release 
was achieved at 1 h time point, and about 97% of drug was released at 24 h. This could be the 
result of release-retardation effect of Kollidon® SR. The release rate of ExtM was faster than the 
ExtT in first 8 h, because the higher surface area of ExtM could have more contact with 
dissolution medium. Interestingly, the dissolution curve of ExtM and ExtT overlapped 
completely after 8 h, which indicated all materials of ExtT were exposed to dissolution medium, 
just like what happened in ExtM. This should be because ExtT expanded enough to make room 
for dissolution medium to get inside the tablets (disintegration was not observed during whole 
dissolution process). Ext exhibited the slowest release profile. Less than 15% of theophylline 
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release was observed after 24 h dissolution. This was because of the highly condensed nature of 
Ext. When materials were pushed out of the die, the high pressure existing at this area would 
compact the material a lot, which resulted in increased density and less cavity [145]. These 
properties would prevent the diffusion of dissolution medium into the center of Ext, thus 
decrease the release. 
 
Figure 4-3. In-vitro release profiles. 
 
Slower release of theophylline in ExtT, compared to that of DCT, was anticipated in the 
beginning. Because theophylline was expected to be better covered by Kollidon® SR after HME 
process, which would slow down the release of API. Actually, this was true when the release of 
PM and ExtM was compared. However, the ExtT and DCT dissolution result was totally 
reversed. This may be owing to the water sorption ability of these two tablets. The morphology 
of tablets before and after dissolution were compared (Figure 4-4). ExtT swelled much more than 
the DCT did, which indicated the ExtT could absorb more water into itself, hence increased 
release. 
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                                      a                                                                              b 
   
                                      c                                                                                 d 
Figure 4-4. Macro photograph of tablets morphology before and after dissolution of: (a) & (b) 
ExtT, (c) & (d) DCT. 
 
4.4.3. Water Sorption Ability 
Macro image of tablets was just a subsidiary characterization method of water sorption 
behavior. Thus, the DVS was utilized to directly detect this property. The study condition was set 
at 37 oC and 100% RH to mimic the dissolution condition. It is necessary to point out that the RH 
achieved at stable state was only 98%, which may due to the instrument limit. This condition 
might have some effect on the results at some point. The water sorption behavior of each 
samples was summarized in Figure 4-5 and Table 4-1. Theophylline barely absorbed any water 
during the process. Only 0.22% gain in weight was recorded by the instrument. Kollidon® SR, on 
76 
the contrary, absorbed moisture equal to around 33% of its own weight. The moisture sorption 
data correlated very well with the dissolution data. More water sorption would lead to faster and 
higher drug release. The only exception would be ExtT and ExtM. Both of them achieved 96% 
of drug release, but the water sorption amount was different. This could be explained by the 
different time range of two experiments. These two materials obtained the same drug release at 8 
h in dissolution study. But the water sorption study lasted less than 5 h. 
 
  
a 
    
                                       b                                                                                c 
Figure 4-5. Dynamic vapour sorption measurements of: (a) theophylline, (b) Ext, (c) DCT 
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                                       d                                                                              e 
    
                                        f                                                                               g 
Figure 4-5. Dynamic vapour sorption measurements of: (d) ExtT, (e) ExtM, (f) PM, (g) 
Kollidon® SR. 
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Table 4-1. Maximum water sorption and time duration data. 
 
Maximum water sorption 
% 
Time of water sorption 
min 
Theophylline 0.22 17.24 
Ext 11.68 277.89 
DCT 14.02 254.56 
ExtT 16.58 267.77 
ExtM 21.57 218.01 
PM 22.10 220.03 
Kollidon® SR 33.29 365.15 
 
4.4.4. Water Sorption Pathway 
The DVS study had clearly revealed the correlation of sample water sorption ability with 
API release speed as well as extent, i.e., theophylline in ExtT released more and faster than that 
of DCT. To better understand the process of drug release at real time, the water sorption pathway 
study was also conducted. In short, the original dissolution medium was dyed to blue color so 
that the pathway that the dissolution medium was absorbed by both tablets could be easily 
recorded and compared. The cross-section comparison of both tablets at different time points was 
shown as in Figure 4-6. The picture was adjusted by photoshop to provide better contrast 
between wetted and unwetted part. From the picture, it was clear that the water entered both 
tablets from the out layer to inner layer. However, at the endpoint of 24 h, ExtT was fully soaked 
by the water, which make the whole tablet blue. However, DCT still showed some of the original 
color of material at the same time point. This result conformed with the DVS study result very 
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well, which was ExtT absorbed more water than DCT. At each time point, more area of ExtT, 
compared to that of DCT, was wetted by the water at the same time point. This phenomenon 
indicated the water is more difficult to diffuse into DCT than ExtT. 
 
 
Figure 4-6. Dissolution Medium Sorption Pathway 
 
4.4.5. Tablet Structure Test 
To better explain this phenomenon above mentioned, both the surface structure and 
interior structure of ExtT and DCT were checked with SEM (Figure 4-7). From the surface 
structure perspective, more amount and bigger size crevices was found on the ExtT. Water could 
easily enter in the center of the tablets, and absorbed by Kollidon® SR in situ. However, the 
crevice on DCT was less and smaller, which limited the entrance of water directly. Diffusion was 
the major mechanism for water absorption, which was less efficient. The interior structure was 
achieved by manually breaking tablets, no knifes were used. However, the fracture face of DCT 
was quite smooth, as cut by knife. This indicated the strength of connection between particles is 
quite similar to the particle interior strength. Thus, when broken by hand, either the individual 
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particle could be broken or particles could be departed from each other. In comparison, 
individual particles could be easily distinguished in ExtT. This indicated the connection between 
particles is much weaker than the strength of particles itself. In the dissolution scenario, water 
could easily pass through the particle gap of ExtT, instead of DCT. Thus, the absorption of 
dissolution medium is much faster in ExtT than DCT.  
Thus, it could be concluded that release of theophylline in the formulation mainly 
depended on water absorbed by the Kollidon® SR. The process could be in 4 steps. Firstly, water 
entered the system either by absorption of Kollidon® SR or the crevice of tablet surface. 
Secondly, water moved inward the tablet through the particle gap, Thirdly, theophylline was 
solubilized by the water absorbed. Lastly, theophylline diffused out and released. 
      
                                          a                                                                      b 
      
                                         c                                                                        d  
Figure 4-7. Surface structure of a) DCT, b) ExtT and Interior structure of c) DCT, d) ExtT 
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CHAPTER 5. 
SUMMARY AND CONCLUSION 
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Over the last few decades, twin screw extruder (TSE) has attracted considerable attention 
in the pharmaceutical industry as an alternative processing instrument due to its advantages 
compared to other conventional equipment, such as economical processing, small footprint, 
reduced in-process times, solvent-free and continuous processing. These superiorities have led to 
the application of twin-screw extruder to produce numerous dosage forms, including pellets, 
tablets and films. Many other formulations production can also be beneficial from the 
introduction of twin-screw extruder to the process. In a series of studies, the application of TSE 
has extended for a further step. 
In chapter 2, The use of a novel conjugation of HPH and HME techniques to 
continuously produce NCSD was investigated. This technique helps to overcome the nanocrystal 
formulation problems that are associated with the conventional methods. By using this technique, 
an increase in the dissolution rate was achieved as a result of the decreased particle size and 
increased surface area, and also owing to the improved wettability. The good stability was 
attributed to the maintained crystalline state of the drug. 
In chapter 3, the previously unreported study of applying twin screw extruder to the dry 
granulation process was successfully conducted. The effect of various factors on the granule 
properties was clearly revealed by performing a Resolution V Irregular Fraction Design. 
Automatic Optimization of processing parameters to achieve the setting goal was achieved by 
utilizing the obtained model. In general, TSDG was demonstrated to be an alternative method to 
prepare dry granules. The continuous processing nature, simplicity of operation and easiness of 
optimization made TSDG quite competitive compared to other conventional dry granulation 
techniques. 
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In chapter 4, the different behavior of ExtT and DCT under the same dissolution 
environment were compared. The mechanism behind this different behavior was further 
investigated by the water absorption study, dissolution medium absorption tracking study as well 
as the tablet structure analysis. In general, different structures determined the different water 
sorption property of tablets, which finally resulted in different dissolution behavior.  
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